XML 43 R23.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information and Geographic Data
12 Months Ended
Dec. 31, 2025
Segment Information and Geographic Data  
Segment Information and Geographic Data

17. Segment Information and Geographic Data

The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is on developing and commercializing novel therapies that target cardiovascular diseases with significant unmet medical need. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer. The Company’s CODM reviews consolidated operating results and decides how to allocate resources based on net income that also is reported on the income statement as consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes net income to make key decisions about how to allocate resources across the Company’s commercial product and development programs.

The following table presents selected financial information with respect to the Company’s single operating segment for the years ended December 31, 2025, 2024 and 2023:

Years Ended

December 31, 

  ​ ​ ​

2025

2024

  ​ ​ ​

2023

Revenue:

Product revenue, net

$

677,564

$

417,029

$

233,176

License and collaboration revenue

-

6,210

37,083

Total revenue

677,564

423,239

270,259

Operating expenses:

Cost of goods sold

77,673

60,910

33,407

Collaboration expenses

229,545

128,311

56,524

Direct research and development expenses by program:

ARCALYST

1,040

1,080

2,628

KPL-387

47,265

11,221

2,537

KPL-1161

4,198

581

-

Abiprubart

6,122

59,459

28,388

Vixarelimab

44

1,530

7,717

Unallocated research and development expenses

38,184

37,752

34,827

Selling, general and administrative

196,272

168,011

129,427

Total operating expenses

600,343

468,855

295,455

Other income, net (1)

11,647

9,464

8,544

Income (loss) before income taxes

88,868

(36,152)

(16,652)

Benefit (provision) for income taxes

(29,863)

(7,041)

30,736

Net income (loss)

$

59,005

$

(43,193)

$

14,084

Other significant non-cash items:

 

 

 

Share-based compensation expense

$

37,003

$

30,693

$

27,149

Non-cash lease expense

3,666

3,136

3,054

Deferred income taxes

13,002

8,132

(33,788)

(1)Includes interest income of $11,636, $9,036 and $8,227 for the years ended December 31, 2025, 2024 and 2023 respectively.

The following table presents total revenue by geographic region of the customer for years ended December 31, 2025, 2024 and 2023:

Years Ended

December 31, 

2025

2024

  ​ ​ ​

2023

Revenue:

United States

$

676,750

$

421,434

$

269,772

United Kingdom

814

930

487

Rest of world

-

875

-

Total revenue

$

677,564

$

423,239

$

270,259

The following table presents property and equipment, net by geographic region:

Years Ended

December 31, 

2025

2024

Property and Equipment, net

United States

$

1,608

$

313

United Kingdom

76

99

Rest of world

259

250

Total property and equipment, net

$

1,943

$

662